vs
Side-by-side financial comparison of PicoCELA Inc. (PCLA) and Stoke Therapeutics, Inc. (STOK). Click either name above to swap in a different company.
PicoCELA Inc. is the larger business by last-quarter revenue ($252.6M vs $158.6M, roughly 1.6× Stoke Therapeutics, Inc.). Stoke Therapeutics, Inc. runs the higher net margin — 71.2% vs -125.2%, a 196.4% gap on every dollar of revenue. Stoke Therapeutics, Inc. produced more free cash flow last quarter ($131.7M vs $-256.6M).
PicoCELA Inc. is a global technology company specializing in low-power, high-reliability wireless connectivity solutions, including Wi-Fi HaLow modules and edge network infrastructure. It caters to industrial IoT, smart city, retail, and smart home segments, with a primary operational footprint across Asia, North America, and European markets.
Stoke Therapeutics, Inc. is a clinical-stage biotechnology company developing innovative RNA-targeted therapies for severe rare genetic diseases. Its lead candidates address unmet needs for Dravet syndrome, a rare epilepsy, and other neurological monogenic disorders, serving patients across North America and global markets.
PCLA vs STOK — Head-to-Head
Income Statement — Q2 FY2025 vs Q1 FY2025
| Metric | | |
|---|---|---|
| Revenue | $252.6M | $158.6M |
| Net Profit | $-316.2M | $112.9M |
| Gross Margin | — | — |
| Operating Margin | -114.8% | 70.2% |
| Net Margin | -125.2% | 71.2% |
| Revenue YoY | — | 3661.1% |
| Net Profit YoY | — | 528.0% |
| EPS (diluted) | — | $1.90 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 25 | $252.6M | $158.6M | ||
| Q4 24 | — | $22.6M | ||
| Q2 23 | — | $-2.5M |
| Q1 25 | $-316.2M | $112.9M | ||
| Q4 24 | — | $-10.5M | ||
| Q2 23 | — | $-30.7M |
| Q1 25 | -114.8% | 70.2% | ||
| Q4 24 | — | -60.4% | ||
| Q2 23 | — | 1340.7% |
| Q1 25 | -125.2% | 71.2% | ||
| Q4 24 | — | -46.4% | ||
| Q2 23 | — | 1235.6% |
| Q1 25 | — | $1.90 | ||
| Q4 24 | — | $-0.15 | ||
| Q2 23 | — | $-0.69 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $456.8M | $274.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $354.8M | $350.1M |
| Total Assets | $1.2B | $406.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $456.8M | $274.8M | ||
| Q4 24 | — | $128.0M | ||
| Q2 23 | — | $192.1M |
| Q1 25 | $354.8M | $350.1M | ||
| Q4 24 | — | $229.0M | ||
| Q2 23 | — | $190.2M |
| Q1 25 | $1.2B | $406.9M | ||
| Q4 24 | — | $271.6M | ||
| Q2 23 | — | $256.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-245.6M | $131.8M |
| Free Cash FlowOCF − Capex | $-256.6M | $131.7M |
| FCF MarginFCF / Revenue | -101.6% | 83.0% |
| Capex IntensityCapex / Revenue | 4.3% | 0.1% |
| Cash ConversionOCF / Net Profit | — | 1.17× |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 25 | $-245.6M | $131.8M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-21.8M |
| Q1 25 | $-256.6M | $131.7M | ||
| Q4 24 | — | $-23.2M | ||
| Q2 23 | — | $-22.6M |
| Q1 25 | -101.6% | 83.0% | ||
| Q4 24 | — | -102.7% | ||
| Q2 23 | — | 912.5% |
| Q1 25 | 4.3% | 0.1% | ||
| Q4 24 | — | 0.2% | ||
| Q2 23 | — | -33.8% |
| Q1 25 | — | 1.17× | ||
| Q4 24 | — | — | ||
| Q2 23 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PCLA
| Revenue from product | $179.1M | 71% |
| Revenue from SaaS, Maintenance and others | $42.4M | 17% |
| Revenue from product – related party | $31.0M | 12% |
STOK
Segment breakdown not available.
